quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:00:52·29d
ANALYSTRating
Viking Therapeutics Inc. logo

Wolfe Research initiated coverage on Viking Therapeutics

VKTX· Viking Therapeutics Inc.
Health Care
Original source

Companies

  • VKTX
    Viking Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 26UpdateWolfe Research-
  • Oct 29UpdateCanaccord Genuity$106.00
  • Apr 29UpdateCantor Fitzgerald$104.00
  • Apr 8UpdateGoldman$30.00
  • Feb 13UpdateScotiabank$102.00
  • Feb 7UpdateCitigroup$38.00

Related

  • PR1d
    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
  • PR1d
    Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
  • PR14d
    Viking Therapeutics to Participate at Upcoming Investor Conferences
  • SEC22d
    SEC Form DEFA14A filed by Viking Therapeutics Inc.
  • SEC22d
    SEC Form DEF 14A filed by Viking Therapeutics Inc.
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Viking Therapeutics Inc.
  • PR29d
    Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735
  • INSIDER44d
    SEC Form 4 filed by Viking Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022